Construction and application of a mammalian model of pulmonary fibrosis

A technology for mammals and pulmonary fibrosis, applied in the field of experimental zoology, can solve the problems of easy failure and difficulty in building animal models of pulmonary fibrosis, and achieve the effects of high success rate, low animal oral toxicity and great application potential

Active Publication Date: 2022-01-07
QINGDAO UNIV
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The present invention aims to solve the technical problems of difficulties and failures in the construction of animal models of pulmonary fibrosis, and aims to provide an effective method and application for the construction of animal models of pulmonary fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Construction and application of a mammalian model of pulmonary fibrosis
  • Construction and application of a mammalian model of pulmonary fibrosis
  • Construction and application of a mammalian model of pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Using 4-week-old mice of the C57BL / 6N strain, use an ultrasonic nebulizer to ultrasonically nebulize 1 mg / mL polyhexamethylene monoguanidine solution, and the concentration in the exposure box is about 10 mg / m 3 , the mice were exposed for 4 hours, once every other day, for three consecutive exposures.

[0021] After raising the mice for one month, the mice were dissected pathologically, and the lung tissue was stained with hematoxylin-eosin to observe the fibrosis lesions of the lung tissue. It was found that the lung tissue had fibrosis-like changes, the alveolar wall was thickened, and the alveolar collapsed. , uneven distribution, a large number of inflammatory cell infiltration, consistent clinical symptoms of pulmonary fibrosis.

Embodiment 2

[0023] Using 4-week-old Balb / c strain mice, inject 0.1 mL of 2 mg / mL polyhexamethylene biguanide solution into the airways of the mice using a tracheal infusion needle, inject once, and raise the mice for one month. The mice were dissected, and the collagen deposition in the lung tissue was observed using Masson's trichrome staining technique. It was found that there was obvious collagen deposition in the lung tissue, indicating that pulmonary fibrosis lesions appeared in the lungs of the mice.

Embodiment 3

[0025] Using 8-week-old SD rats, inject 0.2 mL of 3 mg / mL polyhexamethylene biguanide solution into the airway of the rats with a tracheal infusion needle, inject once, and after feeding the rats for one month, dissect the rats , using a-SMA antibody to stain the lung tissue of rats, observe the expression of lung tissue fibrosis markers, and find that the lung tissue fibrosis marker a-SMA is significantly expressed, indicating that pulmonary fibrosis lesions appear in the lungs of rats, the model The build was successful.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of experimental zoology and provides the application of polyhexamethylene monoguanidine or polyhexamethylene biguanide in establishing a mammalian model of pulmonary fibrosis. The present invention also provides a method for constructing a mammalian model of pulmonary fibrosis, which includes the following steps: exposing the mammal to an environment containing polyhexamethylene monoguanidine or polyhexamethylene biguanide, polyhexamethylene The inhaled amount of methyl monoguanide or polyhexamethylene biguanide is 10% of the mammalian body weight ‑8 ~10 ‑6 and continue feeding for 20-40 days to obtain the mammalian model of pulmonary fibrosis. The present invention also provides the application of the pulmonary fibrosis mammalian model obtained by the above method in the study of the pathogenesis of pulmonary fibrosis and therapeutic drugs.

Description

technical field [0001] The invention belongs to the field of experimental zoology, and in particular relates to the application and method of a cationic guanidine polymer compound in establishing a mammalian model of pulmonary fibrosis. Background technique [0002] Pulmonary fibrosis is a major respiratory disease that affects human health, and its etiology has not yet been fully studied. Clinically, drugs for the treatment of pulmonary fibrosis can only alleviate the process of pulmonary fibrosis, but cannot cure this type of disease. Medical-assisted treatment can prolong the life of patients to a certain extent, but the radical cure of pulmonary fibrosis requires in-depth research on its pathogenesis to find specific drugs for treatment. The pathogenesis of pulmonary fibrosis and the development of effective intervention methods are current research hotspots. Therefore, it is necessary to simulate the process of pulmonary fibrosis in clinical patients in vitro, so as to...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A01K67/00A61K49/00
CPCA01K67/00A61K49/0008A01K2227/10A01K2267/03
Inventor 唐敬龙郑玉新祝肖肖
Owner QINGDAO UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap